Process optimisation in development of biosimilars

Opublikowany: 29.11.2023

Process optimisation for biologics is obligatory for efficient processing and reduction of Cost of Goods (COGs). Especially in the development of biosimilars.

In the current issue of European Biotechnology, Louis Boon (Chief Scientific Officer at Bioceros) describes advantages of using Bioceros’ CHO-BC® platform, easy to transfer to the development laboratories of Polpharma Biologics, in process optimization.

Learn more about metabolic control of this platform using two novel technologies called SPOT™ and SLIM™ as well as how these technologies can help your developments.


written by: Polpharma Biologics

Współpracujmy, aby dostarczać wysokiej jakości leki biopodobne.

Skontaktuj się, aby uzyskać więcej informacji.